(Immuno)proteasomes as therapeutic target in acute leukemia

The clinical efficacy of proteasome inhibitors in the treatment of multiple myeloma has encouraged application of proteasome inhibitor containing therapeutic interventions in (pediatric) acute leukemia. Here, we summarize the positioning of bortezomib, as first-generation proteasome inhibitor, and s...

Descripción completa

Detalles Bibliográficos
Autores principales: Cloos, Jacqueline, Roeten, Margot SF, Franke, Niels E, van Meerloo, Johan, Zweegman, Sonja, Kaspers, Gertjan JL, Jansen, Gerrit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721123/
https://www.ncbi.nlm.nih.gov/pubmed/29071527
http://dx.doi.org/10.1007/s10555-017-9699-4
_version_ 1783284759505403904
author Cloos, Jacqueline
Roeten, Margot SF
Franke, Niels E
van Meerloo, Johan
Zweegman, Sonja
Kaspers, Gertjan JL
Jansen, Gerrit
author_facet Cloos, Jacqueline
Roeten, Margot SF
Franke, Niels E
van Meerloo, Johan
Zweegman, Sonja
Kaspers, Gertjan JL
Jansen, Gerrit
author_sort Cloos, Jacqueline
collection PubMed
description The clinical efficacy of proteasome inhibitors in the treatment of multiple myeloma has encouraged application of proteasome inhibitor containing therapeutic interventions in (pediatric) acute leukemia. Here, we summarize the positioning of bortezomib, as first-generation proteasome inhibitor, and second-generation proteasome inhibitors in leukemia treatment from a preclinical and clinical perspective. Potential markers for proteasome inhibitor sensitivity and/or resistance emerging from leukemia cell line models and clinical sample studies will be discussed focusing on the role of immunoproteasome and constitutive proteasome (subunit) expression, PSMB5 mutations, and alternative mechanisms of overcoming proteolytic stress.
format Online
Article
Text
id pubmed-5721123
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-57211232017-12-12 (Immuno)proteasomes as therapeutic target in acute leukemia Cloos, Jacqueline Roeten, Margot SF Franke, Niels E van Meerloo, Johan Zweegman, Sonja Kaspers, Gertjan JL Jansen, Gerrit Cancer Metastasis Rev Article The clinical efficacy of proteasome inhibitors in the treatment of multiple myeloma has encouraged application of proteasome inhibitor containing therapeutic interventions in (pediatric) acute leukemia. Here, we summarize the positioning of bortezomib, as first-generation proteasome inhibitor, and second-generation proteasome inhibitors in leukemia treatment from a preclinical and clinical perspective. Potential markers for proteasome inhibitor sensitivity and/or resistance emerging from leukemia cell line models and clinical sample studies will be discussed focusing on the role of immunoproteasome and constitutive proteasome (subunit) expression, PSMB5 mutations, and alternative mechanisms of overcoming proteolytic stress. Springer US 2017-10-25 2017 /pmc/articles/PMC5721123/ /pubmed/29071527 http://dx.doi.org/10.1007/s10555-017-9699-4 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Article
Cloos, Jacqueline
Roeten, Margot SF
Franke, Niels E
van Meerloo, Johan
Zweegman, Sonja
Kaspers, Gertjan JL
Jansen, Gerrit
(Immuno)proteasomes as therapeutic target in acute leukemia
title (Immuno)proteasomes as therapeutic target in acute leukemia
title_full (Immuno)proteasomes as therapeutic target in acute leukemia
title_fullStr (Immuno)proteasomes as therapeutic target in acute leukemia
title_full_unstemmed (Immuno)proteasomes as therapeutic target in acute leukemia
title_short (Immuno)proteasomes as therapeutic target in acute leukemia
title_sort (immuno)proteasomes as therapeutic target in acute leukemia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721123/
https://www.ncbi.nlm.nih.gov/pubmed/29071527
http://dx.doi.org/10.1007/s10555-017-9699-4
work_keys_str_mv AT cloosjacqueline immunoproteasomesastherapeutictargetinacuteleukemia
AT roetenmargotsf immunoproteasomesastherapeutictargetinacuteleukemia
AT frankenielse immunoproteasomesastherapeutictargetinacuteleukemia
AT vanmeerloojohan immunoproteasomesastherapeutictargetinacuteleukemia
AT zweegmansonja immunoproteasomesastherapeutictargetinacuteleukemia
AT kaspersgertjanjl immunoproteasomesastherapeutictargetinacuteleukemia
AT jansengerrit immunoproteasomesastherapeutictargetinacuteleukemia